We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ulta Beauty (ULTA - Free Report) posted mixed Q3 earnings and forecast after the closing bell today, and stocks are down in late trading on the news. Earnings of $1.70 per share beat the Zacks consensus by 3 cents, while revenues of $1.34 billion were exactly in-line with expectations. Ecommerce was up 62% year over year, and guidance for Q2 has been raised from our $1.92 billion consensus, but shares are selling off in the after-hours based on lowered guidance for Q4 earnings. For more on ULTA's quarterly results, click here.
VMware also topped expectations after market close, putting up $1.34 per share, when the consensus was for $1.27. Revenues of $1.98 billion narrowly edged out the $1.96 billion Zacks analysts were looking for. Sales rose 11% year over year. The company did not provide guidance for next quarter nor fiscal year. For more on VMW's earnings, click here.
Cloud services firm Nutanix (NTNX - Free Report) reported better-than-expected results for its fiscal Q1 2018, posting a bottom-line loss of 16 cents per share on $275.6 million in sales for the quarter, up 46% year over year. These numbers beat the -26 cents and $266.7 million in the Zacks consensus estimates. The company expects fiscal Q2 revenues to be in-line with estimates ($280-285 million), but a narrower loss per share -- -20 cents to -22 cents, as opposed to the consensus -25 cents. For more on NTNX's quarterly results, click here.
Even though specialty retailer Zumiez (ZUMZ - Free Report) outperformed on the top line and met the bottom line estimate after today's bell, shares are selling off in late trading. 48 cents per share equaled the Zacks consensus, and $245.8 million in quarterly sales, up 11%, edged out the $242.9 million expected. ZUMZ is trading down 3% in the late market, however, after cruising up 17% in the last 5 trading days. For more on ZUMZ's earnings, click here.
Finally, Five Below (FIVE - Free Report) beat on both top and bottom lines in its most recent quarter, on the strength of 29% growth in sales year over year. The company posted a 5-cent beat on the bottom line to 18 cents per share, on $257 million in sales that far outperformed the expected $245 million. The maker of fidget spinners also raised guidance for both earnings and revenues for next quarter and next year. For more on FIVE's earnings, click here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Q3 Results for Specialty Retail Continue
Ulta Beauty (ULTA - Free Report) posted mixed Q3 earnings and forecast after the closing bell today, and stocks are down in late trading on the news. Earnings of $1.70 per share beat the Zacks consensus by 3 cents, while revenues of $1.34 billion were exactly in-line with expectations. Ecommerce was up 62% year over year, and guidance for Q2 has been raised from our $1.92 billion consensus, but shares are selling off in the after-hours based on lowered guidance for Q4 earnings. For more on ULTA's quarterly results, click here.
VMware also topped expectations after market close, putting up $1.34 per share, when the consensus was for $1.27. Revenues of $1.98 billion narrowly edged out the $1.96 billion Zacks analysts were looking for. Sales rose 11% year over year. The company did not provide guidance for next quarter nor fiscal year. For more on VMW's earnings, click here.
Cloud services firm Nutanix (NTNX - Free Report) reported better-than-expected results for its fiscal Q1 2018, posting a bottom-line loss of 16 cents per share on $275.6 million in sales for the quarter, up 46% year over year. These numbers beat the -26 cents and $266.7 million in the Zacks consensus estimates. The company expects fiscal Q2 revenues to be in-line with estimates ($280-285 million), but a narrower loss per share -- -20 cents to -22 cents, as opposed to the consensus -25 cents. For more on NTNX's quarterly results, click here.
Even though specialty retailer Zumiez (ZUMZ - Free Report) outperformed on the top line and met the bottom line estimate after today's bell, shares are selling off in late trading. 48 cents per share equaled the Zacks consensus, and $245.8 million in quarterly sales, up 11%, edged out the $242.9 million expected. ZUMZ is trading down 3% in the late market, however, after cruising up 17% in the last 5 trading days. For more on ZUMZ's earnings, click here.
Finally, Five Below (FIVE - Free Report) beat on both top and bottom lines in its most recent quarter, on the strength of 29% growth in sales year over year. The company posted a 5-cent beat on the bottom line to 18 cents per share, on $257 million in sales that far outperformed the expected $245 million. The maker of fidget spinners also raised guidance for both earnings and revenues for next quarter and next year. For more on FIVE's earnings, click here.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>